|
INPP4A expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62447832963153E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.62447832963153E-12 |
| Normal-vs-Stage2 |
1.041540E-02 |
| Normal-vs-Stage3 |
9.97535387625703E-12 |
| Normal-vs-Stage4 |
6.57619514399244E-11 |
| Stage1-vs-Stage2 |
2.762900E-03 |
| Stage1-vs-Stage3 |
5.522800E-01 |
| Stage1-vs-Stage4 |
8.563600E-01 |
| Stage2-vs-Stage3 |
2.138200E-02 |
| Stage2-vs-Stage4 |
1.145650E-02 |
| Stage3-vs-Stage4 |
5.447600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
1.035060E-04 |
| Normal-vs-Asian |
8.11661848842959E-12 |
| Caucasian-vs-AfricanAmerican |
9.674000E-01 |
| Caucasian-vs-Asian |
4.929600E-01 |
| AfricanAmerican-vs-Asian |
7.198200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.04719566351719E-11 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
3.148400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
<1E-12 |
| Normal-vs-Age(41-60Yrs) |
2.38697950294409E-14 |
| Normal-vs-Age(61-80Yrs) |
1.04509999998559E-06 |
| Normal-vs-Age(81-100Yrs) |
1.252170E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.458300E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.716600E-03 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.179830E-02 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.727800E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.737600E-02 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.558800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.898600E-01 |
| Classical-VS-Follicular |
2.22044604925031E-16 |
| Classical-VS-Other |
1.156440E-01 |
| Classical-VS-Normal |
1.62436730732907E-12 |
| Tall-VS-Follicular |
8.75699999958179E-07 |
| Tall-VS-Other |
1.718150E-01 |
| Tall-VS-Normal |
5.20220533317683E-11 |
| Follicular-VS-Other |
2.493600E-01 |
| Follicular-VS-Normal |
1.592160E-01 |
| Other-VS-Normal |
9.473700E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
9.20200027287876E-10 |
| Normal-vs-N1 |
7.44500017191285E-11 |
| N0-vs-N1 |
5.626200E-02 |
|
|
